Open-label extension data showed that disability trends observed with vidofludimus calcium during the double-blind period of the phase 2 CALLIPER trial persisted with continued treatment in ...
AV-1959R is an investigational amyloid-beta vaccine from Nuravax. The FDA granted it Fast Track designation for preventing Alzheimer disease in cognitively unimpaired people with biomarker evidence of ...
Clene has filed an NDA seeking accelerated approval of CNM-Au8 for ALS, following 2 missed primary trial endpoints and years of evolving FDA guidance. Catch up on any of the neurology headlines you ...
FcRn inhibition targets the persistence of pathogenic IgG rather than its production. The panel explains why this downstream ...
One-year data from the phase 3 AQUARELLE study show that divozilimab (Biocad), an anti-CD20 monoclonal antibody, reduced ...
This episode, titled ‘Differentiating FcRn-Targeted Therapies in MG Clinical Practice,’ features panelists examining ...
Decade of OPERA Data Supports Early Ocrelizumab Treatment Initiation in Relapsing Multiple Sclerosis
A newly published study showed that patients with relapsing multiple sclerosis (RMS) who started ocrelizumab (Ocrevus; ...
Clene has filed an NDA seeking accelerated approval of CNM-Au8 for ALS, following 2 missed primary trial endpoints and years ...
A four-year-old with regression, ptosis, and feeding problems illustrates the textbook features of severe early-onset TK2D ...
This week on NeurologyLive, there are a number of hot topics that we will be post ...
Intravenousocrelizumab (Ocrevus; Genentech) demonstrated noninferiority to oral fingolimod (Gilenya; Novartis) for ...
Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Nicholas J. Maragakis, MD; and Jinsy Andrews, MD, MSc, FAAN, FANA. [LISTEN TIME: 23 minutes] ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results